Lurbinectedin: A New Treatment Option for Relapsed/Refractory Small-Cell Lung Cancer.
Lauren T ShinnKatrina A VoDavid J ReevesPublished in: The Annals of pharmacotherapy (2020)
With a promising OR compared with other second-line options, lurbinectedin should be considered in patients who have failed first-line therapy. Studies are ongoing with lurbinectedin in combination with other agents in SCLC, and a phase III trial is assessing use in combination with doxorubicin compared with other second-line regimens.
Keyphrases
- phase iii
- small cell lung cancer
- open label
- clinical trial
- end stage renal disease
- phase ii
- ejection fraction
- chronic kidney disease
- prognostic factors
- acute lymphoblastic leukemia
- drug delivery
- double blind
- study protocol
- randomized controlled trial
- stem cells
- diffuse large b cell lymphoma
- brain metastases
- replacement therapy